Serge Braun has been named to the position of vice president, research at Transgene (Strasbourg, France). Dr. Braun joined Transgene in 1995 as a scientist in the molecular and cellular biology department, and served most recently as deputy vice president, research.

MDS Pharma Services (Montreal, PQ, Canada) has announced the appointment of Peter Chiu as pharmacology director and associate research fellow. Dr. Chiu will also assume scientific oversight of the company's facility in Taipei, Taiwan, as acting chief scientific officer.

Applied Molecular Evolution (San Diego, CA) has announced the appointment of Stanley T. Crooke to its board of directors. Dr. Crooke was formerly president of R&D for SmithKline Beecham, and is the founder, chairman, and CEO of Isis Pharmaceuticals.

Patrik Dahlén has been appointed chief executive of BioImage A/S (Copenhagen, Denmark). Dr. Dahlén was formerly president of the life sciences division of PerkinElmer.

Patricia Fukami has been appointed vice president of finance at diaDexus (Santa Clara, CA). She joins diaDexus from http://Healthcentral.com, where she served as vice president of finance and administration and assisted in the company's initial public offering in December 1999.

Renovis has announced the appointment of Corey Goodman as president, chief executive officer, and director. Dr. Goodman, the Evan Rauch Professor of Neuroscience and director of the Willis Neuroscience Institute at the University of California, Berkeley, co-founded the company in February 2000.

Esperion Therapeutics (Ann Arbor, MI) has elected Antonio M. Gotto Jr. to its board of directors. Dr. Gotto is a professor of medicine as well as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University.

Abgenix (Fremont, CA) has appointed Bruce A. Keyt to the position of vice president, preclinical development. Dr. Keyt was most recently director of biotherapeutic oncology at Millennium Pharmaceuticals.

Richard Klausner has stepped down as director of the National Cancer Institute, a position he has held since 1995. He will become president of the Case Institute of Health, Science and Technology, a new philanthropic enterprise created by the Case Foundation, the family foundation of AOL Time Warner chairman Steve Case and his wife Jean.

GPC Biotech AG (Martinsried, Germany and Waltham, MA) has announced the appointment of Steven R. Lazar as vice president, worldwide head of intellectual property. Mr. Lazar was previously managing intellectual property counsel at Genzyme.

Henri Lipmanowicz has been named to the board of directors of Immuno-Designed Molecules (Paris). Mr. Lipmanowicz recently retired after a 30-year career at Merck & Co., where he was a member of the management committee and president of the Merck Intercontinental Region and Japan. He is currently chairman of the board of trustees of the Plexus Institute.

Sangamo BioSciences (Point Richmond, CA) has announced the appointment of Carl O. Pabo as senior vice president and chief scientific officer. Dr. Pabo comes to Sangamo after 10 years as professor of biophysics and structural biology at the Massachusetts Institute of Technology and investigator in the Howard Hughes Medical Institute.

Tony Scullion, formerly vice president and head of global business development at Glaxo Wellcome plc, has been named CEO of Memory Pharma- ceuticals (Montvale, NJ).

Genome Therapeutics (Waltham, MA) has appointed David K. Stone to its board of directors. Mr. Stone is a founding partner of the venture capital group AGTC Funds, and was previously managing director at Cowen & Company (now SG Cowen).

Genencor International (Palo Alto, CA) has named David Thomassen vice president, business development of health care. Dr. Thomassen joins Genencor after serving as director of business development at Chiron.

Roman Urfer has been appointed vice president of drug discovery and development at AGY Therapeutics (South San Francisco, CA). Previously, Dr. Urfer served as head of the mature drug discovery program in the department of arthritis biology at Novartis Pharma AG.

CeNeS Pharmaceuticals (Cambridge, UK) has named Dan Welch to its board as a non-executive director. He is currently president of Elan Pharmaceuticals.